drugset / Trial / NCT01455935
Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention
Phase 2
Unknown
90 enrolled
Jacobs Neurological Institute
Genentech, Inc. · collabUniversity at Buffalo Neurosurgery · collab
RandomizedFactorialSingle-blindTreatment
Summary
The purpose of the trial is to study the safety and the effectiveness of using CT Perfusion studies as an indicator to treat stroke patients with unknown time of onset.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-12
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 0.9 mg/kg | Intravenous |
| Comparator | ASA | Unknown | 81 mg | Oral |
| Comparator | Aggrenox | Unknown | 225 mg | Oral |
| Comparator | Atorvastatin | Small molecule | 80 mg | Oral |
| Comparator | Clopidogrel | Small molecule | 75 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 20 mg | Oral |